Please login to the form below

Not currently logged in
Email:
Password:

Maxcess Managed Markets appoints new MD

James Harmon has been appointed as managing director and executive vice president of Maxcess Managed Markets

James Harmon has been appointed as managing director and executive vice president of Maxcess Managed Markets, a speciality provider of strategic market insight, planning, research, and communications services to the pharmaceutical industry.

Harmon has more than 20 years of experience in the pharmaceutical industry with managed markets, marketing, global market access, sales leadership, customer management, commercial development and operations experience.

Most recently Harmon was an executive advisor with the managed markets practice and the pharmaceutical institute for Campbell Alliance, whose clients include top-tier pharmaceutical and biotech companies as well as smaller and growing firms.

Prior to Campbell Alliance, Harmon served as vice president of Managed Markets and was a member of the executive leadership team for Organon, US. At Organon, he led the managed markets transformation from a tactical to strategic function that was fully integrated across the marketing and sales organisations, generating significant financial results, strategic process and marketing improvements for the company.

Mike Trepicchio, president of Publicis Health Care Communications Group (PHCG) North America Advertising, of which Maxcess is a subsidiary, said: "Market access is an increasingly critical issue, as health 2.0 and environmental constraints pressure the pharmaceutical industry to evolve its economic model as well as its customers."

He continued: "Jim's talent for 'demystifying' managed markets and engaging all stakeholders for success and shared accountability makes him the perfect fit at the helm of Maxcess."

Harmon said: "Maxcess' disciplined approach to managed markets marketing and results-driven philosophy make the firm an industry standout. I am eager to leverage my experience and that of the Maxcess teams to add to the intellectual value capital driving our clients' success."

8th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics